# Downstream Purification & Bioseparation

Downstream purification converts crude bioreactor harvests into clinical-grade drug substance — chromatography (Protein A, IEX, HIC), tangential-flow filtration, and viral clearance together account for >50% of biomanufacturing CAPEX. The global DSP market exceeds $5B and grows at >8% CAGR driven by mAb and cell-gene therapy demand.

Source: https://en.bioecon.ru/technology/downstream-purification-bioseparation/
Updated: 2026-08-18



## Overview and value chain

Markers: [EC: EudraLex Volume 4 GMP Annex 2 (biologics) | OECD: 2.8 Industrial biotechnology | Regulator: FDA (US), EMA (EU)]

Downstream processing (DSP) transforms crude bioreactor harvests into purified, sterile, and formulated drug substance meeting ICH Q6B purity specifications (>99% for mAbs). The global biopharma DSP market exceeded $5B in 2025, growing at >8% CAGR fueled by >1,000 mAbs in clinical pipelines and >200 approved cell-gene therapies. A standard three-step platform process — Protein A capture (>99% IgG selectivity), anion-exchange polishing (HCP<100 ppm), and viral filtration (6-log clearance) — recovers >90% of expressed antibody at >99.5% purity. DSP costs represent 50–70% of total biomanufacturing OPEX per gram of mAb; reducing purification costs by 10% unlocks $300M+ in industry-wide savings annually. Continuous DSP (multi-column chromatography + ATF perfusion) cuts resin consumption by 3–4× and OPEX by 20–30% versus batch processes.

The key directions of downstream purification & bioseparation are:
1. **Affinity Chromatography Capture (Protein A, Protein G):** Protein A resins (TOYOPEARL Super A, MabSelect PrismA) bind IgG Fc region with Kd ≈ 10^-9 M; dynamic binding capacity >55 mg/mL; alkali-stable variants withstand >200 CIP cycles with 0.5 M NaOH.
2. **Continuous & Periodic Counter-Current Chromatography (PCC):** Multi-column setups (2–4 columns) increase resin utilization from 40% to >80%; Novasep Hipersep and Cytiva ÄKTA periodic counter-current systems demonstrate 3× productivity gain per column volume.
3. **Membrane Chromatography & Adsorbers:** Single-use quaternary ammonium (Q) membrane adsorbers (Sartobind Q, Mustang Q) process >10× the flow rates of resin columns with <2 min residence time; ideal for polishing steps at commercial scale.
4. **Tangential-Flow Filtration & ATF Perfusion:** TFF concentrates protein 10–20× and achieves diafiltration buffer exchange (<5 ppm residual solvent); Repligen XCell ATF enables cell culture densities >100M cells/mL and harvest titre >10 g/L in perfusion mode.

### Sectoral value chain

```
[Harvest Clarification] ──> [Capture (Protein A)] ──> [Viral Inactivation] ──> [Polishing (IEX/HIC)]
                                       │
                             (affinity resin)
                                       │
                                       ▼
[Final Formulation] <─── [Viral Filtration] <─── [UF/DF Concentration] <────┘
```

### Value chain levels

| Level | Description | Key inputs/outputs |
|:---|:---|:---|
| **Harvest Clarification** | Centrifugation + depth filtration remove cells, debris, and aggregates from bioreactor harvest | **In:** Cell culture broth, 3–15 g/L titre.<br>**Out:** Clarified harvest, turbidity <5 NTU, >95% yield. |
| **Affinity Capture** | Protein A chromatography binds mAb selectively from complex harvest; acid elution at pH 3.4–3.8 | **In:** Clarified harvest.<br>**Out:** Captured mAb, >95% purity, 1–10 g/L pool, HCP <10,000 ppm. |
| **Viral Inactivation** | Low-pH hold (pH 3.4–3.8, 30–60 min) inactivates enveloped viruses; >4-log reduction required by ICH Q5A | **In:** Capture eluate.<br>**Out:** Virally inactivated pool; mandatory regulatory hold step. |
| **Ion-Exchange Polishing** | AEX in flow-through mode removes HCP, DNA, aggregates; CEX removes charge variants | **In:** Neutralized virus-inactivated pool.<br>**Out:** HCP <100 ppm, aggregates <0.5%. |
| **Viral Filtration** | 15–20 nm pore-size filters (Viresolve Pro, Virosart) provide >4-log virus clearance by size exclusion | **In:** Polished pool.<br>**Out:** Virus-cleared permeate; regulatory clearance contribution. |
| **UF/DF & Formulation** | TFF concentrates to target >100 mg/mL; diafiltration exchanges into final formulation buffer | **In:** Viral filtrate, excipient buffer.<br>**Out:** Formulated drug substance at target concentration for fill-finish. |

Cross-cutting technologies of the sector:
- **Process Analytical Technology (PAT — UV, MALS, pH):** Inline UV absorbance, multi-angle light scattering (MALS), and pH monitoring provide real-time yield and purity feedback; regulatory expectation since FDA PAT guidance (2004), now mandatory in many CMC submissions.
- **Single-Use Flow Paths (SU-DSP):** Pre-sterilized single-use TFF cassettes, column hardware, and membrane adsorbers eliminate CIP/SIP cycles, reduce changeover time by 60%, and are standard in >70% of new biopharma DSP installations.
- **Continuous Chromatography (BioSMB, PCC):** Periodic counter-current and simulated moving bed systems (Novasep, Cytiva, Sartorius) are entering clinical manufacture; >15 approved biopharmaceuticals manufactured with continuous DSP components as of 2025.

---

## US

The US leads globally in mAb DSP innovation, driven by FDA's continuous manufacturing guidance (2019), the CMC trend toward intensified processes, and the concentration of large-scale biologics CDMOs (Lonza Biologics, Fujifilm Diosynth, Samsung Biologics US sites) adopting next-generation DSP platforms.

### FDA continuous manufacturing guidance, single-use DSP adoption, mAb platform process dominance
- **Repligen (Waltham, MA):** XCell ATF perfusion retentors and KrosFlo TFF systems dominate US biologics CDMOs; Opus pre-packed columns enable rapid tech transfer with <2-day column qualification; recovering from 2023 biotech destocking, 2025 revenue >$791M.
- **Bio-Rad Laboratories (Hercules, CA):** Nuvia mixed-mode resins (wPrime 2A: AEX-HIC) and Nuvia HR-S (CEX) increasingly adopted for platform polishing; CHT Ceramic Hydroxyapatite remains standard for non-Protein-A formats (IgM, Fc-fusions).
- **FDA Annex 21 CFR Part 211/610:** >85% of US mAb manufacturing uses Protein A platform; FDA inspection focus shifting to HCP method validation (ELISA specificity >95%) and viral clearance comparability post-scale-up.

---

## CN

China's DSP market is growing at >12% CAGR as domestic biosimilar manufacturers (BioAtla, CSPC, Hengrui) invest in GMP-grade downstream platforms; the 14th Five-Year Plan targets 100% domestic resin supply for strategic biologics by 2027, driving investments in CN-made Protein A resin substitutes.

### domestic-resin-substitution drive, biosimilar-manufacturing scale-up, NMPA GMP alignment
- **Nanjing NISCO (CN):** Domestic Protein A resin manufacturer — AmiStar A resin competitive at <50% of imported cost; NMPA-approved for clinical-stage mAb purification; >20 domestic biosimilar projects using AmiStar by 2025.
- **14th Five-Year Plan — Biopharma Equipment Localization:** CNY 2B investment in domestic chromatography resin and TFF membrane manufacturing; target: >50% domestic supply for approved biological drugs by 2027.
- **Cytiva Greater China:** ÄKTA chromatography systems and MabSelect PrismA Protein A resin remain #1 by installed base in CN; local customer service center expanded by 40% in 2024 to support NMPA GMP alignment program.

---

## EU

The EU is the birthplace of Protein A chromatography (Uppsala University / Pharmacia, 1970s), and Europe's DSP industry is anchored by Cytiva (Uppsala), Sartorius (Göttingen), and Novasep (Lyon), with Tosoh's EU distribution and growing continuous chromatography adoption among EU CDMOs.

### EMA GMP Annex 2 continuous-process guidance, Cytiva ÄKTA platform dominance, viral-clearance regulatory stringency
- **Cytiva (Uppsala, Sweden):** ÄKTA pure, ÄKTA pilot, and ÄKTA process remain the reference chromatography platforms globally; MabSelect SuRe and PrismA Protein A resins cover >60% of globally installed mAb capture capacity; ÄKTA crossflow TFF system for UF/DF.
- **Sartorius (Göttingen, Germany):** Sartobind Q membrane adsorbers (anion-exchange, single-use) and Sartobind Rapid A (Protein A membranes) enable 100× faster processing than resin columns for polishing steps; BIA Separations (Sartorius subsidiary) specializes in CIMmultus monolith columns for viral vector purification.
- **Novasep (Pompey, France):** Hipersep preparative HPLC and multi-column chromatography (MCC/PCC) for small-molecule and biologic APIs; EU GMP viral clearance validation services on-site; acquired by CDPQ and Novo Holdings 2022; focused on EU biopharmaceutical outsourcing market.

---

## Leading companies and research institutes

| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|:---|:---|:---|:---|:---|
| **Cytiva** | 🇸🇪 Sweden | *MabSelect PrismA, ÄKTA systems, ReadyToProcess* | Protein A + IEX + TFF full DSP suite; #1 installed base globally | ~4B revenue; Danaher subsidiary; ÄKTA dominates >60% capture capacity |
| **Repligen** | 🇺🇸 USA | *XCell ATF, KrosFlo TFF, Opus columns* | ATF perfusion >100M cells/mL; pre-packed SU columns | $791M FY25 revenue; NASDAQ: RGEN; recovering post-destocking |
| **Bio-Rad** | 🇺🇸 USA | *Nuvia wPrime, Nuvia HP-Q, CHT Hydroxyapatite* | Mixed-mode AEX-HIC; CHT for IgM/Fc-fusion polishing | $2.8B total revenue; NYSE: BIO; DSP ~15% |
| **Tosoh Bioscience** | 🇯🇵 Japan | *TOYOPEARL Super A, TSKgel, HIC/SEC/IEX resins* | Alkali-resistant Protein A; low ligand leaching; HPLC columns | Tosoh group ¥350B; bioscience growing >8% YoY |
| **Sartorius** | 🇩🇪 Germany | *Sartobind Q, Sartobind Rapid A, BIA monoliths* | Membrane adsorbers; CIMmultus for AAV/lentivirus purification | €3.38B revenue; SRT.DE; recovering from 2023 downcycle |
| **Novasep** | 🇫🇷 France | *Hipersep PCC/MCC, preparative HPLC* | Continuous multi-column chromatography; EU GMP viral clearance | ~€200M; EU CDMO focus; CDPQ + Novo Holdings ownership |

---

## Tech stack and innovations

Downstream purification is undergoing a platform shift — from batch stainless-steel resin columns to continuous, single-use, intensified processes that cut CAPEX by 30–50% and time-to-GMP by 40% for new biologics programs.

1. **Protein A Affinity Resins (Next-Gen Alkali-Stable):**
   - TOYOPEARL Super A (Tosoh) and MabSelect PrismA (Cytiva) withstand >200 CIP cycles with 0.5 M NaOH; binding capacity >55 mg IgG/mL resin; new rigid particle sizes (45–90 µm) enable >800 cm/h linear velocity.
   - Domestic CN equivalents (NISCO AmiStar, JSR KanCapA) achieving >80% MabSelect-equivalent performance at <50% cost; entering EU submissions as parallel resins.
2. **Continuous Chromatography (PCC / BioSMB):**
   - Periodic counter-current (Cytiva ÄKTA pcc, Novasep Hipersep) reduces Protein A resin consumption by 3–4×; buffer consumption drops 40% — enabling >20% OPEX savings on a 2,000 L bioreactor process.
   - Integrated with ATF upstream perfusion, a fully continuous mAb process (harvest-to-bulk) now achieves >95% yield in <5 days for clinical-scale batches.
3. **Membrane Adsorbers (Single-Use Polishing):**
   - Sartobind Q and Mustang Q process polishing loads at 3–6× the linear velocity of resin columns (1,000+ cm/h); single-use eliminates 48-hour CIP/requalification cycles between batches.
   - BIA Separations CIMmultus monolith columns (8 mL – 8 L) dominate viral vector (AAV, lentiviral) polishing with >90% yield and 10–20× faster processing than beads.
4. **ATF Perfusion Harvest (Repligen XCell ATF):**
   - Alternating tangential flow eliminates gravity-driven settling; filter fouling rate <20% over >21-day continuous runs; scalable from 0.5 L (development) to 5,000 L (commercial).
   - Harvest titre multiplier: 5–10× higher than fed-batch for high-expression clones; reduces downstream load volume by equivalent factor, cutting resin and membrane costs proportionally.
5. **Process-Scale MALS & PAT Integration:**
   - Inline multi-angle light scattering (Wyatt MALS, Malvern) measures aggregate content in real time during TFF concentration steps; triggers automated dilution cycles if aggregation exceeds 0.1%.
   - Digital twin models (Cytiva SIMCA-P+, Sartorius BioPAT) predict column bed compression and resin lifetime, enabling predictive maintenance and GMP deviation prevention.

---

## Value chains and production pipelines

### Industrial pipeline of mAb downstream purification (ICH Q6B / EudraLex GMP Annex 2)

```
┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Harvest & Clarification│ ───> │ 2. Protein A Capture      │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. IEX/HIC Polishing      │ <─── │ 3. Viral Inactivation     │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Viral Filtration       │ ───> │ 6. UF/DF & Formulation    │
└───────────────────────────┘      └───────────────────────────┘
```

#### Stage 1: Harvest & Clarification
Bioreactor harvest broth (3–15 g/L titre, >95% viability preferred) is first centrifuged (disc-stack at 5,000–15,000 × g) to remove cells, then passed through depth filters (diatomaceous earth, 0.22–2 µm) to reduce turbidity to <5 NTU and reduce HCP by 3–5×. Single-use centrifuge and depth-filter assemblies now cover >70% of new clinical facilities.

#### Stage 2: Protein A Capture
The clarified harvest is loaded onto Protein A resin columns at 3–6 min residence time; dynamic binding capacity >50 mg/mL at >90% breakthrough capacity. Elution at pH 3.4–3.8 releases bound mAb; pool yield typically >95% with HCP <5,000 ppm. Regeneration with 0.5 M NaOH is standard; lifetime >200 cycles for alkali-stable resins.

#### Stage 3: Viral Inactivation
Eluate is held at pH 3.4–3.8 for 30–60 min at controlled temperature to achieve ≥ 4-log inactivation of enveloped viruses (retrovirus, BVD); ICH Q5A regulatory requirement. Precise pH control (± 0.05 pH units) is critical to avoid antibody aggregation during this step. After hold, pH is raised to 5.0–7.0 for subsequent polishing.

#### Stage 4: IEX/HIC Polishing
Anion-exchange chromatography (AEX) in flow-through mode removes HCP, DNA, and endotoxins (>99.9% reduction) while mAb passes unretained at pH 7.0–8.0. Optional cation-exchange (CEX) step resolves charge variants. Membrane adsorbers (Sartobind Q) at high flow rates replace resin columns for flow-through polishing in >30% of new commercial platforms.

#### Stage 5: Viral Filtration
15–20 nm pore-size filters (Millipore Viresolve Pro, Sartorius Virosart HF) provide >4-log clearance of non-enveloped viruses (parvovirus B19, MVM); filter loading >500 L/m² typical before flux decay. Single-use capsule format requires no sanitization and enables rapid lot-to-lot changeover.

#### Stage 6: UF/DF & Formulation
TFF membranes (5–30 kDa PES or RC, Cytiva, Repligen KrosFlo) concentrate drug substance to target 100–200 mg/mL for high-concentration subcutaneous formulations. Diafiltration (5–7 volumes of formulation buffer) reduces process-related impurities to ICH limits. Final drug substance is sterile-filtered (0.22 µm) and dispensed for fill-finish or frozen storage at -80°C.